FDA Panel Recommends Relaxing Restrictions on Peptides

An advisory panel for the Food and Drug Administration (FDA) has advised reducing the restrictions on certain peptides, despite government scientists expressing concerns over scant evidence regarding their safety and efficacy.

Peptides, which have gained traction among wellness influencers and celebrities, are lauded for their purported antiaging and anti-inflammatory benefits. The panel’s guidance could permit specific pharmacies to produce substances like BPC-157, KPV, and TB-500, making them available to patients through prescriptions.

The Pharmacy Compounding Advisory Committee of the FDA, with a vote of 8-6 and one abstention on Thursday, suggested adding these peptides to the agency’s 503A bulk drug substances list. This measure does not equate to FDA approval but represents a nonbinding recommendation. If embraced, state-licensed compounding pharmacies and physicians could manufacture them under specified conditions. Although the FDA often aligns with panel recommendations, it is not obligatory.

Health Secretary and Experts’ Views on Peptides

Health Secretary Robert F. Kennedy Jr. openly supports peptides, campaigning against restrictions introduced under the Biden administration. Reports from MedPage Today indicate new panel members appointed by the Health Secretary are linked to peptide-related business interests. Newsweek reached out to HHS for comments outside standard working hours.

However, the panel’s verdict has raised alarm among some experts. Dr. Pieter Cohen, an associate professor at Harvard University, highlighted that there is insufficient evidence supporting these peptides’ safety for human consumption or their claimed health benefits.

The safety of these compounds are unknown in humans. If they were to increase the risk of cancer or heart disease, we wouldn’t know. — Dr. Pieter Cohen

Understanding Peptides

Peptides are short chains of amino acids, components of proteins. They naturally occur in the body and regulate various processes such as inflammation and tissue repair.

BPC-157, derived from amino acids in human gastric juice, has shown antioxidant and wound-healing effects in animal studies. Still, comprehensive clinical research on humans is lacking. KPV, a three-amino-acid peptide from the pituitary gland, is studied for mitigating inflammation in different models. Yet, human implications remain unproven. TB-500, related to thymosin beta-4, is linked with cardiac and wound repair in preclinical investigations, but substantial clinical data on humans is scarce.

Why Use Peptides?

Peptides are popular in wellness and biohacking sectors, marketed for muscle recovery, antiaging, and energy, although unsupported by FDA-approved claims. Demand is encouraged by potential findings in cell and animal studies suggesting benefits like reduced inflammation.

The peptide market is expanding. Market Research Future projected its growth from $43.12 billion in 2024 to $91.79 billion by 2035, with the North American market currently dominant, closely followed by rapid growth in the Asia-Pacific region.

Increased interest is evident from growing U.S. Google searches about acquiring and questioning the safety of peptides. Peptidesexplorer.com reported a 1,019 percent surge in searches from March 2025 to February 2026, with the term “are peptides safe” registering 27,100 U.S. searches in February 2026.

Safety Concerns

The FDA indicates inadequate evidence on the safety and efficacy of BPC-157, KPV, and TB-500, with some products’ chemical identities poorly characterized. There is also an immunogenicity risk for injectables.

The panel is scheduled to assess three additional peptides—emideltide for opioid withdrawal and insomnia, semax for migraines, and epitalon for insomnia. Emideltide has a longer research history going back to 1981, but conclusive evidence on its benefits and safety remains absent.

Process of Experimental Drug Review

Dr. Cohen criticized the proceedings, suggesting they deviate from typical experimental drug review processes where expert panels debate drug safety and efficacy based on comprehensive evidence.

Experimental new drugs that lack evidence of efficacy or safety would not be presented to an FDA panel. The peptide decisions undermine the very principle that the FDA will approve drugs only after careful clinical trials have been completed. — Dr. Pieter Cohen